Not only are you having trouble staying on the MiMedx message board, but now you can't even correctly read the messages on the Osiris board. You need some remedial help and fast.
Well, I haven't been "Stopped Out" and I don't blame other board members for the current share price erosion.
Grafix is going international, Stryker predicts $199 million in sales and it is very obvious that the private Arthrex has their Sales machine in gear for Cartiform. You'd have to be a dunce not to see the long term prospects here...do I need to tell you more or do you want to just keep brooding over your loses?
Still bitter over being "Stopped out" of Osiris. That's pretty lame blaming a board poster for your investment mistakes. Time to take responsibility for your own investment decisions!
Don't have to "catch" while MDXG is dropping like a rock. You better run back to the MiMedx message board, you're losing that imaginary 15x profit fast. Pretty soon you'll being saying you bought MDXG at a nickel.
Your beloved MiMedx is being wiped off the map day by day and your imaginary 15x profits are vanishing right before your eyes. You'll soon be posting good things about Osiris, but using another ID.
Everyone knows LIVE cells beats dry DEAD cells all day long...well...everyone but you.
You're having trouble with your math! MiMedx growth rate has slowed down from 7.3% to 5.4% just last quarter. Better wake up from your dream world before it is too late.
If you are so confident why the constant slamming? You seem very worried and you're keeping your finger on the buy trigger. Must not be sleeping well at night!
Whatever the amount, the money will probably come from MiMedx' past customers, since they are beginning to realize they've been hoodwinked into an inadequate product. MiMedx sales growth is slowing down from 7.3% to 5.4%. Now there is something funny!
Okay, now lets hear your next joke and don't say MiMedx...the FDA is already laughing about that one.
Ever notice how the bashers can't stand the facts and only respond with comedic quips? I don't think MiMedx has ever made a single multi-million dollar product sale in their life. Osiris has had many:
Sold Osteocel to NuVasive for about $85 million.
Partnered Prochymal with Genzyme for around $130 million.
Sold their Therapeutic business to Mesoblast for $50 million upfront cash and securities with another $50 million in milestones plus Sales royalties.
Partnered BIO4 with Stryker for $5 million upfront cash plus Sales royalties.
This is why Osiris has NO DEBT and has three great products; Grafix, BIO4 and Cartiform recently launched in the marketplace. And...they have three more new products; Menvivo, TruSkin and Stravix getting ready to launch.
There is a real future being built at Osiris, and in my opinion, no Hocus Pocus products like some competitors might do.
Too bad MiMedx has never made it to $22, they just don't have the gusto to do much of anything and now you're down to your last hope...begging for a buyout!
Indeed, this is a very dynamic market space!
Have you looked at the FDA Trial database for MiMedx' DFU Epifix? There is only one trial listed which was run way back in 2013 and it is the one where the judging panel was seated with two paid MiMedx employees and had only 13 handpicked Epifix patients versus 12 comparative patients. Is there any surprise that they received good results? They've been living off that low quality trial ever since and have never bothered to run a high quality trial. Why us that? In my opinion, I think it is because a high quality trial would never confirm the results of their first trial.
Osiris has always run high quality multi-center independently judged trials. That takes longer, a lot longer and it is very expensive, but Osiris never shy's away from QUALITY and the market will eventually see the difference between quality products or products with shortcut procedures.
The bashers will always retort by saying another trial is not needed and that Epifix Sales figures are the final word. But, what they are not telling you is that the Epifix Sales growth rate is falling and has fallen from 7.3% to 5.4% from last quarter.
Osiris is taking the high road and this race is not over yet!
Apparently you've already had blood vessel leakage as no sane person would ever Spam a stock until their fingers bleed. And by the way, that loop you're in could likely end up being your financial noose if you continue to stay Short.
You guys are worrying so much about Osiris that you are letting your beloved MiMedx slip away...down, down, down and headed for the $6 handle. Try slapping your forehead instead of your knee and perhaps the rattling sound will wake you up.
1) First marketing authorization received in the U.S. $20 million
2) First marketing authorization received from France, Germany, or European Union. $10 million
3) Completion of the enrollment of the Phase 3 Crohn’s Trial or Mesoblast’s election to discontinue the trial $10 million. Final data collection is scheduled for July 2017, therefore my guess is we may see this money somewhere around the end of 2016 or early 2017.
4) Receipt of final data for the Crohn’s trial or first marketing approval for Crohn’s $10 million
(Final data is scheduled for July 2017.)
Osiris is guaranteed to receive a minimum of $10 million dollars from Mesoblast or stock equivalency and is illegible to receive up to a total of $50 million in milestone payments.
Osiris is on a rock solid financial foundation with over $40 million in cash, no debt and at a minimum, arrived at the break-even point in earnings. More than likely though they are now in positive earnings territory.
I see you have trouble with sarcasm, perhaps you should go back to your favorite message board MiMedx...oh! that's right, no one will talk to you over there..
It'll probably take about 6 months to gather up all the data and tabulate, but this is great news coming down the pike. Too bad it will take that long, but it does take quite an effort tracking down any missing pieces, correcting spellings, dotting all the i's and crossing all the t's. The data has to be perfect before it can be released.
Get the information from the same place the "no where near $100 million" claim came from? Maybe smallinfinity can help you!
We just have the knuckle heads piling on right now and spinning everything way out of proportion. The reality is...Osiris has Grafix that is currently selling at the least $25 million per quarter and that is a $100 million annual run rate. Companies generally sell a product line to another company at ratio of 5 to 6 times Sales. A simple valuation of 5x makes the Grafix product line worth $500 million or $14.49 a share, if it was "For Sale". This valuation doesn't even include BIO4 or Cartiform, therefore today's share price is a steal and certainly doesn't reflect the true value of Osiris.
The broad market will "wake up" to this reality in a few more weeks and realize they've gone overboard.